IDEXX Q4 revenue $954M (+6% YoY), EPS $2.62; guides 2025 rev $4.06-$4.17B, EPS $11.74-$12.24

IDEXX LABORATORIES INC /DE

2024-FY EPS reported $10.67 revenue$3,897,504,000

Q4 revenue $954M (+6% reported and organic); CAG Diagnostics recurring revenue +7% organic.
Q4 EPS $2.62 (+13% as reported, +10% comparable); full year EPS $10.67 (+12% comparable).
2025 revenue guidance $4.055-$4.170B (+4-7% reported, +6-9% organic); EPS $11.74-$12.24 (+10-15% reported).
Expects ~$1.5B in share repurchases in 2025 (~4% of market cap), subject to market conditions.
2024 full year revenue $3.898B (+6% as reported and organic); targets 200-250 bps operating margin improvement in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.